Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

PCO25-209: Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Inhibition of ER Positive Breast Cancers in Acquired Resistance PDX Model
Gil, Małgorzata , Alderson, Meera, D’Assoro, Antonio B., Li, Shunqiang , Yu, Tao , Alderson, Meera, Takabe, Kazuaki , Opyrchal, Mateusz

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7309 Get It

Market-Level Features May Influence a Hospital’s Decision to Perform Robotic Radical Cystectomy in Florida
Qosja, Neda, Spaulding, Aaron , Zganjar, Andrew , Borkar, Shalmali R. , Pathak, Ram , Lyon, Timothy D. , Zganjar, Andrew J., Lyon, Timothy D , Spaulding, Aaron , Colibaseanu, Dorin

Urology Practice | March 28, 2025 | Volume: 12 | Issue: 4 | Pages: 391-400

10.1097/upj.0000000000000816 | PMID 40152667 Get It

HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era
Okcu, Izel, Nowakowski, Grzegorz S. , Amengual, Jennifer E. , Ross, Che, Bock, A., Okcu, Izel , Pierce, Andrew L., Tolu, Seda , Graber, Jerome J. , Hu, Boyu , Ermann, Daniel A.

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7347 Get It

CRE25-036: Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC): A Mayo Clinic Multidisciplinary Approach to Treatment
Prasad, Dhauna Karam, Corbin, Kimberly S. , Solanki, Malvika , Block, M.S., O’Sullivan, Ciara C. , Hieken, Tina J. , Mardini, Samir , Markovic, Svetomir N.

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7109 Get It

QIM25-237: Supporting Oncologists in Capturing and Using Structured Oncology Data in Real-Time Using the Electronic Health Record (EHR)
Tevaarwerk, Amye J., Gatten, Clare A., Simret, Teshome, Carroll, Jamie M. , Advani, Pooja , Chumsri, Sarayana, Mandrekar, Sumithra J. , Giridhar, Karthik V. , Chumsri, Sarayana, Jin, Zhaohui

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7350 Get It

CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC)
Hoyek, Celine , Pirozzi, Angelo , Zheng-Lin, Binbin , Lida, N., Ramaker, Ryne C. , Abidoye, Seyi, Wu, Christina, Ahn, Daniel H. , Rimassa, Lorenza, Rimassa, Lorenza , Rimassa, Lorenza , Eslinger, Cody , Shibuki, Taro , Sonbol, Mohamad Bassam , Borad, Mitesh J. , Ikeda, Masafumi , Nakamura, Yoshiaki , Yoshino, Takayuki , Strickler, John H. , Bekaii‐Saab, Tanios

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7161 Get It

Moderate alcohol-associated hepatitis: A real-world multicenter study
Idalsoaga, Francisco , Díaz, Luis Antonio , Dunn, Winston , Muñoz, Karen E., Caldentey, Vicente, Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Ramírez, Carolina , Malhi, Gurpreet, Ahmed, Adan, Homsi, Hoomam , Abid, Zinia, Echavarría, Victor, Poca, María , Cuyàs, Berta , Ventura‐Cots, Meritxell , Higuera‐de‐la‐Tijera, Fátima , Ayala-Valverde, María , Pérez, Diego , Gómez, Jaime , Abraldes, Juan, Al‐Karaghouli, Mustafa , Jalal, Prasun K. , Ibrahim, Mohamad Ali , García–Tsao, Guadalupe , Havaj, Daniel Ján , Sulejova, Karolina, Chacko, Kristina R. , Yaquich, Pamela, Toro, Luis, Shah, Vijay H. , Kamath, Patrick S. , Mehta, Heer , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Sarin, Shiv Kumar , Maiwall, Rakhi , Qian, Steve , Simonetto, Douglas A , Singal, Ashwani K , Ramirez-Cadiz, Carolina , Poca, Maria , Soriano, German , Cuyas, Berta , Ventura Cots, Meritxell , Higuera-De La Tijera, Fatima , Ayala-Valverde, María , Jalal, Prasun K , Skladaný, Lubomir , Havaj, Daniel J , Chacko, Kristina R , Restrepo, Juan C , Shah, Vijay, Arrese, Marco , Kamath, Patrick S , Bataller, Ramon A , Díaz, Luis A , Elfeki, Mohamed A , Dunn, Winston , Echavaría, Victor , Muñoz, Karen, Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Ahmed, Adan, Abid, Zinia, Cabezas, Joaquín , Abraldeṣ, Juan G. , Goyes, Daniela , Selčanová, Světlana Adamcová , Rincón, Diego , Arrese, Marco , Arab, Juan Pablo

Hepatology Communications | March 28, 2025 | Volume: 9 | Issue: 4 | Pages: No page available

10.1097/hc9.0000000000000673 | PMID 40131003 Get It

Background: Severe alcohol-associated hepatitis (sAH) is a well-characterized disease with high short-term mortality. However, there is limited research on those with a “less severe condition” (moderate AH). This study aims to characterize in-depth patients with moderate AH (mAH), including the performance of mortality scoring systems, key prognostic factors, and survival over time. Methods: A multicenter retrospective cohort study (2009–2019) included patients with mAH (MELD score ≤20 at admission). Cox regression and receiver operating characteristic curves with AUC were used for analysis. Results: We included 1845 patients with AH (20 centers, 8 countries) between 2009 and 2019. mAH was defined as a MELD score ≤20 at admission. Twenty-four percent met the criteria for an mAH episode. Patients with mAH tend to be older and have a higher proportion of females, with a median MELD of 17 (15–19), Maddrey discriminant function (mDF) of 33 (22–40), the trajectory of serum bilirubin of 0.83 (0.60–1.21), and neutrophil-to-lymphocyte ratio (NLR) of 5 (2.96–8.60). The primary causes of death in mAH included multiple organ failure (34.1%) and infections (16.6%). The cumulative survival rates at 30, 90, and 180 days were 94.3%, 90.4%, and 88.2%, respectively. In multivariable analysis, age was the only significant predictor of 30-day mortality (HR 1.49, 95% CI: 1.27–1.76, p <0.001). Mortality prediction models showed poor performance, with AUC for MELD (0.671), mDF (0.726), trajectory of serum bilirubin (0.733), and NLR (0.697). Conclusions: Patients with moderate AH exhibited a mortality of 11.8% at 6 months, primarily driven by multiple organ failure and infections. These patients also exhibit a different clinical profile compared to those with sAH. Tailored models and therapeutic strategies are needed to improve long-term outcomes in mAH.
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment
Raoof, Sana , Dadhania, Seema , Herrick, Brian, Bakshi, Bea, Payling, Miles, Patel, Tushar

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7196 Get It

Selective Elimination of Breast Surgery for Invasive Breast Cancer
Kuerer, Henry M. , Valero, V, Krishnamurthy, Savitri, Diego, Emilia J. , Lin, Heather , Shen, Yu , Mitchell, Melissa P. , Yang, Wei , Group, Exceptional Responders Study, Moseley, Tanya W. , Leung, Jessica WT, Huang, Monica L. , Parra, Raquel FD van la, Teshome, Mediget , Hwang, Rosa F. , Miggins, Makesha, Piotrowski, Matthew J., Refinetti, Ana P, Ehlers, Richard A., Mouabbi, Jason , Colen, Jessica Suarez, Loveland‐Jones, Catherine, Lesnikowski, Beth Ann, Samiian, Laila, Chong, Clayton, Black, Dalliah M. , Desyder, Sarah M, Nguyen, Tuyen , Smith, Benjamin D. , Krishnamurthy, Savitri , Johnson, Helen Margaret , Lucci, Anthony , Shaitelman, Simona Flora , Boughey, Judy C. , White, Richard L., Hunt, Kelly K. , Rauch, Gaiane M. , Group, Exceptional Responders Study, Candelaria, Rosalind P. , Adrada, Beatriz E. , Arribas, Elsa , Ramirez, David Luis , Sun, Susie X.

JAMA Oncology | March 28, 2025 | Volume: 11 | Issue: 5 | Pages: 529

10.1001/jamaoncol.2025.0207 | PMID 40152443 Get It

Importance Neoadjuvant systemic therapy (NST) has been associated with pathologic complete response (pCR) in up to 60% of breast cancers (BCs). The findings of this trial question the necessity of surgery. Objective To report preplanned 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients selected with image-guided vacuum assisted biopsy (VAB). Design, Setting, and Participants This single-arm, prospective, phase 2 nonrandomized clinical trial was conducted at 7 US medical centers and included women 40 years or older with cT1-2N0-1M0 ERBB2 -positive (formerly HER2 -positive) or triple-negative invasive BC who showed residual breast lesions after NST of less than 2 cm on imaging. Enrollment was from March 6, 2017, to November 9, 2021. Data analysis was from October to December 2024. Intervention Image-guided VAB of the tumor bed (9G with a minimum of 12 cores) was performed after standard NST. Patients with clinically node-negative disease at diagnosis and no residual cancer in the breast on post-NST VAB underwent whole-breast radiotherapy with a boost without breast or axillary surgery. Patients with initial documented nodal disease and a breast pCR on VAB underwent targeted axillary dissection, while those with residual cancer when undergoing VAB had standard breast and axillary surgery. Patients were monitored with physical examinations and mammography every 6 months. Main Outcome Measures The primary outcome was ipsilateral breast tumor recurrence. Results Fifty patients (median [IQR] age, 62 [55-77] years) were enrolled and underwent post-NST VAB. Twenty-nine (58%) and 21 (42%) patients had ERBB2 -positive and triple-negative invasive BC, respectively. Breast pCR on VAB was identified in 31 patients (62%; 95% CI, 47.2%-75.34%), and axillary pCR was identified among all 8 patients with initial nodal metastases and breast pCR on VAB who underwent targeted axillary dissection. At a median follow-up of 55.4 (IQR, 44.0-63.5) months, the ipsilateral breast tumor recurrence rate was 0%, and disease-free and overall survival rates were 100% for patients without breast surgery. Conclusions and Relevance The results of this nonrandomized clinical trial that reported preplanned 5-year outcomes suggest that omission of breast surgery in select patients after NST may be feasible, with no recurrences seen. More confirmatory studies are necessary before this new approach alters surgical practice. Trial Registration ClinicalTrials.gov Identifier: NCT02945579